Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma

Respiratory Medicine
Susan LuBarbara A Knorr

Abstract

Phosphodiesterase-4 (PDE4) inhibitors have potential utility as a new therapeutic approach to improving symptoms and pulmonary function in asthma and COPD. This study evaluated the efficacy and safety of MK-0359, a selective and potent oral PDE4 inhibitor, in chronic asthma. Adults (N=88) with > or =1 year asthma history and an FEV(1) 50-80% predicted were randomized to double-blind treatment with MK-0359 (15mg/day) or placebo for 14 days, then crossed-over to the other treatment for 14 days. The primary endpoint was the change from baseline in FEV(1) at the end of each 2-week treatment period. Secondary and other endpoints included the changes from baseline in Daytime asthma symptom score, Nighttime asthma symptom score, Total daily beta-agonist use (puffs/day), AM and PM peak expiratory flow (PEF) and overall asthma-specific quality-of-life. Safety and tolerability were assessed by clinical adverse experiences. MK-0359 significantly improved the primary endpoint (versus placebo): the least-squares mean difference in change from baseline in FEV(1) (L) was 0.09L (95% CI 0.01, 0.18). Endpoints of Daytime asthma symptom score, Nighttime asthma symptom score, Total daily beta-agonist use, AM PEF, PM PEF, and quality-of-life were a...Continue Reading

References

Oct 16, 1999·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·M D ShieldsM Ennis
Apr 15, 2004·Allergy·Matthew MasoliUNKNOWN Global Initiative for Asthma (GINA) Program
Aug 18, 2004·International Journal of Clinical Practice·A Gillissen
Sep 21, 2005·Pharmacology & Therapeutics·Peter J Barnes
Feb 7, 2006·European Journal of Pharmacology·Kian Fan Chung
May 30, 2006·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Eric D BatemanDirk Bredenbröker
Jul 11, 2006·Drug News & Perspectives·Annette AmonIstvan Szelenyi
Dec 13, 2006·Expert Opinion on Investigational Drugs·Claus Kroegel, Martin Foerster
Dec 16, 2006·Current Medicinal Chemistry·Zheng Huang, Joseph A Mancini
Apr 26, 2007·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·J L BrownS J Wilson

❮ Previous
Next ❯

Citations

Aug 27, 2011·Respiratory Research·Berislav BosnjakMichelle M Epstein
Mar 23, 2011·Clinical Reviews in Allergy & Immunology·Amir A ZekiSamuel Louie
May 15, 2015·Expert Opinion on Therapeutic Patents·Paul GlossopKarl Gibson
May 29, 2014·Expert Opinion on Investigational Drugs·Maria Gabriella MateraMario Cazzola
Apr 14, 2012·Current Opinion in Pharmacology·Clive P Page, Domenico Spina
Mar 5, 2018·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jian LuoChun-Tao Liu
Feb 7, 2019·Expert Opinion on Pharmacotherapy·Dhuha Al-SajeeGail M Gauvreau
Jul 23, 2013·American Journal of Physiology. Lung Cellular and Molecular Physiology·Elizabeth A Townsend, Charles W Emala
Jan 27, 2019·Expert Opinion on Investigational Drugs·Polyxeni NtontsiGeorgios Hillas
Oct 24, 2012·Journal of Allergy·Elizabeth A TownsendCharles W Emala

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.